Analyst Price Targets — MRNA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 8, 2026 11:39 am | — | Morgan Stanley | $39.00 | $79.77 | TheFly | Moderna price target raised to $39 from $33 at Morgan Stanley |
| July 7, 2026 11:28 am | — | RBC Capital | $45.00 | $81.80 | TheFly | Moderna price target raised to $45 from $38 at RBC Capital |
| June 26, 2026 1:23 pm | — | Piper Sandler | $77.00 | $67.66 | TheFly | Moderna price target raised to $77 from $69 at Piper Sandler |
| May 4, 2026 1:36 pm | — | UBS | $45.00 | $47.47 | TheFly | Moderna price target raised to $45 from $36 at UBS |
| May 4, 2026 12:36 pm | Luca Issi | RBC Capital | $38.00 | $46.87 | TheFly | Moderna price target raised to $38 from $35 at RBC Capital |
| May 1, 2026 11:40 pm | — | Goldman Sachs | $49.00 | $45.37 | TheFly | Moderna price target raised to $49 from $43 at Goldman Sachs |
| May 1, 2026 5:12 pm | — | Morgan Stanley | $33.00 | $44.18 | TheFly | Moderna price target raised to $33 from $30 at Morgan Stanley |
| March 3, 2026 10:15 pm | Andrew Tsai | Jefferies | $37.00 | $49.83 | StreetInsider | Jefferies Reiterates Hold Rating on Moderna (MRNA): "cash breakeven guidance is clearer" |
| February 17, 2026 2:22 pm | Luca Issi | RBC Capital | $30.00 | $42.54 | TheFly | Moderna price target raised to $30 from $25 at RBC Capital |
| February 17, 2026 12:48 pm | Cory Kasimov | Evercore ISI | $35.00 | $43.19 | TheFly | Moderna price target raised to $35 from $28 at Evercore ISI |
Latest News for MRNA
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell…
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company's late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million,…
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19...
Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MRNA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.